Article type: Research Article
Authors: Tsai, Wen-Chiuan | Chu, Chi-Hong | Yu, Cheng-Pin | Sheu, Lai-Fa | Chen, Ann | Chiang, Hung | Jin, Jong-Shiaw
Affiliations: Department of Pathology, Tri-Service General Hospital,
National Defense Medical Center, Taipei, Taiwan | Division of General Surgery, Department of Surgery,
Tri-Service General Hospital, National Defense Medical Center, Taipei,
Taiwan | Taipei Institute of Pathology, Tri-Service General
Hospital, National Defense Medical Center, Taipei, Taiwan
Note: [] Corresponding author: Jong-Shiaw Jin, M.D., Ph.D., Department of
Pathology, Tri-Service General Hospital, National Defense Medical Center, No.
325, Sec. 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan. Tel.: +886 2
87927155; Fax: +886 2 26913324; E-mail: jsjin@ndmctsgh.edu.tw
Abstract: Objective: The aim of this study was to examine the expression of
matriptase and survivin in breast carcinoma and correlate with
clinicopathological parameters. Methods: Immunohistochemical analysis of
matriptase and survivin were performed in tissue microarray slides of 290
cases, including 11 normal breast tissue; 27 fibrocystic disease; 17
fibroadenoma; 6 atypical ductal hyperplasia; 39 ductal carcinoma in situ, low
grade (DCIS, low grade); 39 ductal carcinoma in situ, high grade (DCIS, high
grade); 27 invasive ductal carcinoma, grade I (IDC, grade I); 78 invasive
ductal carcinoma, grade II (IDC, grade II); and 46 invasive ductal carcinoma,
grade III (IDC, grade III). Results: The average immunostaining scores of
matriptase were 44.1 in normal breast tissue, 52.7 in fibrocystic disease, 76.5
in fibroadenoma, 81.7 in atypical ductal hyperplasia, 133.7 in low-grade DCIS,
and 155.8 in high-grade DCIS. Among 151 breast IDC cases, the average
immunostaining scores of matriptase were 172.7 in grade I, 211.7 in grade II,
and 221.2 in grade III. Additionally, the average immunostaining scores of
surviving also correlate with tumor grades and stages. Conclusions: Higher expressions of matriptase and survivin correlate significantly with
clinicopathological parameters in breast cancer and the malignant potential in
premalignant lesions. In addition, higher survivin expression had poorer
prognosis of breast IDC cases.
Keywords: Atypical ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, matriptase, survivin
Journal: Disease Markers, vol. 24, no. 2, pp. 89-99, 2008
Received 7 January 2008
|
Accepted 7 January 2008
|
Published: 2008
